Tinea Corporis (Quba) and Unani Medicine
- Conditions
- Other specified local infections of the skin and subcutaneous tissue,
- Registration Number
- CTRI/2019/02/017434
- Lead Sponsor
- National Institute Of Unani MedicineNIUM
- Brief Summary
Superficialdermatophytosis of the skin in the form of Tinea corporis *(**Quba*) is a very common infection seen in clinical practice. According to aWorld Health Organization survey on the prevalence of dermatophyte infection itwas found that 20% of people presenting for clinical advice are suffering fromcutaneous fungal infections worldwide.Despite the increasing prevalence of cutaneous dermatophytosisacross the world, and especially in tropics, research in this area has oftenbeen neglected.
UnaniMedicine lacks evidence based anti fungal therapy for dermatophytosis. Althoughthere are formulations which are indicated and tested by for centuries. On thebasis of these incidence, treatment failure (especially in chronic infection)and decreased quality of life due to infection, it is need of hours to conducta trial based on Unani Medicine. Hence, in order to validate and provide effectivemanagement of *Quba (**Tinea Corporis)*, the present study entitled “**Efficacy of *MajoonUshba* and topical application of *MarhamRaal* in *Quba* (*Tinea Corporis)* – A Randomized Standard Controlled Studyâ€** has been designed
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 42
- 1.Clinically diagnosed patients of Quba (confirmed on Direct Microscopy).
- 2.Patients who have agreed to sign the informed consent form and follow the protocol.
- 1.Patients below and above the age of 10 and 60 years respectively.
- 2.Patient suffering from concomitant diseases like psoriasis & Eczema.
- 3.Patient suffering from severe systemic and metabolic diseases.
- 4.Diabetic and HIV patient.
- 5.Pregnant & Lactating Women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.In the present study, the efficacy of the treatment will be determined by decrease in grades from higher to lower i.e. from grade 3 to grade 2, grade 2 to grade 1, grade 1 to grade 0 with each parameter. Grade 0 is the highest level of cure that can be attained by the patient. Baseline or 0 day 10th day, 20th day, 30th day and 40th day of the study 2.The total score includes the scores of colour of the lesion, scaling of the lesion, itching, and margins of the lesion, size of the lesion and KOH mount. Baseline or 0 day 10th day, 20th day, 30th day and 40th day of the study
- Secondary Outcome Measures
Name Time Method 1.Negative KOH Microscopy 2.Dermatology Life Quality Index (DLQI)
Trial Locations
- Locations (1)
OPD/IPD Of National Institute Of Unani Medicine
🇮🇳Bangalore, KARNATAKA, India
OPD/IPD Of National Institute Of Unani Medicine🇮🇳Bangalore, KARNATAKA, IndiaMusab AhmadPrincipal investigator9997498033musabahmad@gmail.com